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Residents in Taiwan are often exposed to marine
microorganisms through seafood and occupational expo-
sure. The number of reported cases of infection attributable
to this organism has increased since the first case was
reported in 1985. The increasing number of cases may be
caused by greater disease activity or improved recognition
by clinicians or laboratory workers. We analyze a clinical-
case series of 84 patients with Vibrio vulnificus infection
from 1995 to 2000 and describe the molecular epidemiolog-
ic features of pathogens isolated from these patients. The
spectrum of clinical manifestations and outcomes, options
of antimicrobial therapy, and virulence mechanisms were
investigated. Results of molecular typing of isolates from
humans and marine environment in this country had a high
genetic divergence among these isolates. Education and
measures are needed to prevent this emerging disease. 
A
wareness of Vibrio vulnificus as a threat to human
health has evolved during the past 30 years (1). In
Taiwan, Yuan et al. first reported V. vulnificus infection in
a patient with septicemia and leg gangrene in Kaohsiung
County in 1985 (2). Chuang et al. described an additional
27 cases during a 5-year period from May 1985 to July
1990 and demonstrated three major discernible syn-
dromes: primary septicemia, wound infection, and gas-
trointestinal diseases. The disease had a high mortality rate
(41%) (3). Chuang et al.’s report was also the first to
demonstrate the recurrent nature of this disease. Since
then, many clinicians and researchers from Taiwan have
reported risk factors and the clinical spectrum of this dis-
ease on the basis of an increasing number of reported cases
(4–12). Many factors have been associated with increased
vulnerability of Taiwanese people to V. vulnificus infec-
tion. These include the high prevalence of hepatitis B or C
virus infection-related hepatic diseases (liver cirrhosis and
hepatoma), the environment, and the popularity of prepar-
ing and eating raw or undercooked seafood (3,13). These
factors have drawn considerable interest to finding optimal
therapeutic regimens for this infection, as well as to iden-
tifying the pathogenesis, ecology, and the reservoirs of this
microorganism. 
We describe the clinical features of 84 recently identi-
fied patients with V. vulnificus infection treated from 1995
to 2000 in Taiwan and report the results of molecular typ-
ing of 50 isolates of V. vulnificus from these patients. We
also summarize the recent advances in understanding this
newly recognized disease from the Taiwan perspective. 
Disease Prevalence
Taiwan is a small island situated off the southeast coast
of the Asian continent with a population of >22 million
people. Figure 1 shows the annual number of reported
cases and the estimated prevalence of V. vulnificus infec-
tion (per 106 persons) from 1985 to 2000 in Taiwan (2–12).
Two peaks occurred: one in 1988 to 1990
(0.354–0.450/106 persons) and the other in 1996 to 2000
(0.606–1.237/106 persons). Most reported cases (>90%)
occurred in residents of southern Taiwan. In Taiwan, the
temperature of surface seawater is usually >18°C, except
for February, when it is 17°C–23°C (6). Nearly all cases
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Figure 1. Estimated prevalence (per 106 population) and annual
number of cases of Vibrio vulnificus infection reported from 1985
to 2000 in Taiwan. The line and triangles represent the prevalence
and the bars the number of cases.occurred in the late spring to early fall (April–October),
when the seawater temperature is 20°C–29°C. The peak
months for infections were June–August (summer season)
when the temperature of surface seawater in Taiwan was
approximately 26°C–29°C (6).
The reasons for the increased rate of V. vulnificus dur-
ing the past 2 decades are not fully understood. The extent
to which the increasing number of cases may be caused by
increasing disease activity or improved recognition by cli-
nicians or laboratory workers is also unclear. Since the first
report of V. vulnificus infection in 1987 and subsequent
reports in both humans and environmental studies, clini-
cians in Taiwan have become increasingly aware of the
clinical features of this disease, and laboratory workers
more likely to understand how to isolate and identify this
pathogen accurately. 
Environmental Habitants and Reservoirs
The occurrence of V. vulnificus infections in cultured
shrimp and eels has been reported in Taiwan (14). A
monthly survey on the distribution of Vibrionaceae in sea-
water from five major harbors in Taiwan was conducted
from July 1991 to February 1994 (15). Among the 1,167
Vibrionaceae isolates,  V. vulnificus accounted for 67
(5.7%) (15). This finding indicates that the organism exists
autochthonously around the coastal waters or aquatic habi-
tats in Taiwan. Most isolates (91%) from marine water and
oysters were indole-negative (biotype I) but some
belonged to biotype II (ornithine decarboxylase- and man-
nitol-positive) (16). Strains of V. vulnificus serovar E (also
belonging to biotype II) avirulent for eels, which were
recovered from water and oysters, were reported (17).
Ribotyping analysis of the environmental isolates indicat-
ed a great genetic divergence among these isolates (18).
More than half of the environmental isolates exhibited vir-
ulence in mice, indicating that these isolates might be path-
ogenic to humans (16). In addition, saline and aqueous
ethanol extract (lectins) from some marine algae collected
from the northeastern coast of Taiwan had marked antibac-
terial activity against V. vulnificus isolates recovered from
the northeastern coast of Taiwan (19). Further study is
needed to explore the symbiosis between marine algae and
their associated marine vibrios.
Clinical Features and Outcomes
Clinical information from 84 patients V. vulnificus
infection treated from 1995 to 2000 was obtained from
medical records from five hospitals in Taiwan (Table).
These hospitals, with a capacities of 1,500 to 2,000 beds,
included National Taiwan University Hospital, Taipei;
Chi-Mei Medical Center and National Cheng-Kung
University Hospital, Tainan; Chang Gung Memorial
Hospital-Kaohsiung, Kaohsiung; and Kaohsiung Veterans
General Hospital, Kaohsiung. Most of the patients (73%)
were male. More than 80% of these patients had various
underlying medical conditions with liver disease (particu-
larly hepatitis B or C virus infection-related diseases),
which accounted for more than half of the patients,
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Table. Clinical characteristics of 84 patients with Vibrio vulnificus  
infections who were treated at five major hospitals, Taiwan, 
1995–2000 
Characteristic (no. of patients for whom 
information was available)  
No. of patients (%)  
Sex (n = 84)   
Male/female  61 (72.6)/23 (27.4)  
Age, mean/range (yr)   60/9-87 
Underlying disease (n = 84)
a   
Chronic hepatitis B or C virus infection   10 (11.9) 
Liver cirrhosis   35 (41.7) 
Hepatitis B or C virus infection-related 21 
 Alcoholic  7 
 Hepatoma  7 
Diabetes mellitus   13 (15.5) 
Steroid use  10 (11.9) 
Alcoholism  8 ( 9.5) 
Renal insufficiency   6 (7.1) 
Other malignancies   3 (3.6) 
None  12 (14.3) 
Type of infection (n = 84)   
Cutaneous infection   57 (67.9) 
Cellulitis  15 (17.9) 
 With  bacteremia   5 
  With septic shock   6 
Necrotizing fasciitis   42 (50.0) 
 With  bacteremia   2 
  With septic shock   32 
Primary septicemia   20 (23.8) 
  With septic shock   3 
Spontaneous bacterial peritonitis   6 ( 7.1) 
Meningitis  1 ( 1.2) 
Exposure history (n = 55)    
Injury from handling marine animals   
(fish, crab) 
7 (12.7) 
Preexisting skin wounds   11 (20.0) 
Ingestion of raw seafood   2 ( 3.6) 
None  35 (63.6) 
Initial antibiotic treatment (n = 82)    
A third-generation cephalosporin
b plus 
minocycline 
38 (46.3) 
A first-generation cephalosporin plus an 
aminoglycoside 
15 (18.3) 
Other combinations
c  29 (35.4) 
Surgical treatment   
(cutaneous lesions, n = 57)  
 
Incision and drainage, débridement 
and/or fasciotomy  
43 (75.4) 
Amputation  6 (10.5) 
Outcome   
Survived  57 (67.9) 
Died  25 (29.8) 
Unknown  2 ( 2.4) 
aPatients might have more than two underlying diseases.  
bInclude ceftazidime, cefotaxime, ceftriaxone, and moxalactam.  
cInclude a penicillin or a first -generation cephalosporin plus an 
aminoglycoside or minocycline.  
 followed by diabetes mellitus and steroid use. Nine
patients (16.3%) had exposure to marine injuries (caused
by fish or crab bones or eating raw fish) or marine environ-
ments (swimming in coastal seawater or raising fish).
Although 11 (20%) patients had preexisting skin wounds,
exposure of the skin wounds to salt water was not known.
More than 60% of these patients had a cutaneous infection,
and 50% had necrotizing fasciitis. Approximately three
fourths of the patients with necrotizing fasciitis had septic
shock. Characteristic cutaneous lesions in patients with
necrotizing fasciitis and wounds associated with bac-
teremia attributable to V. vulnificus are shown in Figure 2.
Twenty patients (23.8%) had primary septicemia, and 3
were complicated with septic shock. 
Similar to the previous findings, we found no patients
with gastroenteritis caused by to V. vulnificus (3). Most
patients with gastroenteritis or diarrheal illness in Taiwan
do not seek care at the large teaching hospitals; they also
do not usually have a stool culture, which might explain
the lack of patients with gastrointestinal illness attributable
to V. vulnificus. 
Athird-generation cephalosporin plus minocycline was
used as the definite treatment regimen in 46% of patients.
Among 57 patients with cutaneous lesions, 49 (86.0%) had
some form of surgical treatment (incision and drainage,
débridement, fasciotomy, and amputation). The overall
case-fatality rate was approximately 30% (Figure 3),
which was similar to that reported previously among
patients seen from 1995 to 1990 (3). Patients with sponta-
neous bacterial peritonitis had the highest case-fatality rate
(50%), followed by necrotizing fasciitis (40.5%). Patients
with cellulitis had the lowest case-fatality rate (6.7%).
Antimicrobial Drug Resistance 
and Treatment Options
MICs were determined and interpreted by using the
MIC interpretive criteria for Enterobacteriaceae recom-
mended by the National Committee for Clinical
Laboratory Standards (20–23). All isolates of V. vulnificus
in Taiwan, which were collected from the previous studies,
were susceptible to the following agents (MIC90): ampi-
cillin (1 µg/mL), carbenicillin (4 µg/mL), cephalothin (4
µg/mL), cefamandole (2 µg/mL), cefotaxime (<0.03–0.06
µg/mL), ceftriaxone (<0.03 µg/mL), cefoperazone (0.12
µg/mL), aztreonam (8 µg/mL), imipenem (<0.03–0.12
µg/mL), gentamicin (4 µg/mL), amikacin (8 µg/mL), tetra-
cycline (0.25 µg/mL), minocycline (0.06–0.25 µg/mL),
chloramphenicol (0.5 µg/mL), and fluoroquinolones:
ofloxacin (<0.03  µg/mL), lomefloxacin (0.12 µg/mL),
ciprofloxacin (<0.03–0.03  µg/mL), levofloxacin (0.03
µg/mL), moxifloxacin (0.06 µg/mL), gatifloxacin (0.06
µg/mL), and sparfloxacin (0.06 µg/mL) (20–23). Few iso-
lates were not susceptible to ceftazidime (MIC 32 µg/mL)
and moxalactam (MIC 32 µg/mL) (21). All isolates were
resistant to clindamycin (MICs >256 µg/mL) (20). In vitro
synergism between cefotaxime and minocycline against V.
vulnificus isolates was documented by time-kill study (21).
Time-kill study also demonstrated that fluoroquinolones at
concentrations of two times the MIC had a persistent
inhibitory effect on V. vulnificus for >48 hours (23).
In vivo study using a mouse model of V. vulnificus
infection clearly indicated that combination therapy with
cefotaxime and minocycline is distinctly superior to thera-
py with cefotaxime or minocycline alone (22). A similar
effect of newer fluoroquinolones as single agents com-
pared with the cefotaxime-minocycline combination was
also demonstrated in the treatment of severe experimental
V. vulnificus infection (23).
On the basis of the in vitro and in vivo animal studies,
along with clinical outcome analysis, combination therapy
with cefotaxime (2 g every 6 h intravenously) and minocy-
cline (100 mg every 12 h intravenously) was recommend-
ed for treating adult patients with bacteremia and severe
soft-tissue infection caused by V. vulnificus (21,22). For
severe soft-tissue infection (necrotizing fasciitis, tissue
necrosis with gangrene change, and myositis), early and
aggressive surgical interventions (incision and drainage,
débridement, fasciotomy, and amputation) are important in
saving the life of the patient. 
Pathogenesis
More than 90% of V. vulnificus isolates whose biotypes
were determined belonged to biotype I, which is well
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Figure 2. Characteristic skin lesions of Vibrio vulnificus infection
and morphotype of the microorganism. A) Gangrenous change
with hemorrhagic bullae over the leg in a 75-year-old patient with
liver cirrhosis in whom septic shock and V. vulnificus bacteremia
developed. B) V. vulnificus bacteremia developed 1 day after a fish
bone injury on the fourth finger of the left hand (arrow) in a 45-
year-old patient with uremia. C) Gram-negative curved bacilli
(arrowhead) isolated from a blood sample of the 45-year-old
patient with uremia.known to be pathogenic for humans (15,16). In 1997,
Chuang et al. first demonstrated that severe damage of the
connective tissue of a mouse by V. vulnificus wound infec-
tion could be mediated by a recombinant extracellular met-
alloprotease (able to digest collagen and elastin) (24). Lee
et al. also illustrated that extracellular products of V. vul-
nificus  were lethal to fish (moribund black porgy,
Acanthopagrus schlegeli) (25). Genes (vvp and  empV)
encoding the metalloprotease and gene (vllY) encoding a
novel hemolysin of V. vulnificus were subsequently cloned
and characterized (26–28). 
Hor et al. showed that isogenic protease-deficient (PD)
mutant of V. vulnificus was as virulent as its parent strains
in mice infected intraperitoneally and was 10-fold more
virulent in mice infected through the oral route (29). A
metalloprotease- and cytolysin-deficient mutant of V. vul-
nificus also had similar virulence in mice, and its cytotox-
icity for HEP-2 cells (cytotoxin) compared with those of
the wild-type strains (30). These findings suggest that nei-
ther metalloprotease nor cytolysin is essential for the viru-
lence or invasiveness of V. vulnificus in mice. A possible
multifactor interaction in bacterial virulence might be
present but to an extent that is not yet clear. However, two
genes,  vvn (encoding a periplasmic nuclease, Vvn) and
smcR (encoding  SmcR, which regulate metalloprotease
gene expression), were not required for V. vulnificus viru-
lence in mice (31,32).
Animal studies clearly demonstrated that iron could
increase the growth rate of V. vulnificus, which quickly
reached a lethal concentration with enhanced cytotoxicity
in the iron-overloaded mice (33). Astudy of the survival of
V. vulnificus in whole blood from patients with different
degrees of liver disease showed that high serum ferritin
levels and low phagocytosis activity of neutrophils were
independent and important predictors of survival of the
organism in blood (34). These findings indicated that
patients with chronic hepatitis, liver cirrhosis, and
hepatoma (high serum ferritin levels and lower phagocyto-
sis) were at high risk for V. vulnificus infection (34).
Although many putative virulence factors have been stud-
ied for this exceptionally virulent human pathogen in
Taiwan, how these factors and other veiled factors (such as
capsular polysaccharide and lipopolysaccharide) interact
to produce dramatic infections and what host aspects (such
as overproduction of proinflammatory cytokines) are
essential to infection are yet to be elucidated (3).
Molecular Epidemiologic Features
Results of molecular typing by using restriction frag-
ment length polymorphism analysis of rRNA (ribotyping)
among 13 clinical and environmental (from seawater and
eels in southern Taiwan) isolates of V. vulnificus and arbi-
trarily primed polymerase chain reaction analysis of 37
isolates (24 clinical isolates and 13 from seawater from
coast areas around Taiwan) were previously reported
(18,35). Both showed high genetic divergence among clin-
ical and environmental isolates. 
The concentration of V. vulnificus in recent clinical and
environmental isolates in southern Taiwan indicates the
possibility of clonal spread in this area. In this study, 50
isolates of V. vulnificus collected from 1995 to 2000 from
southern (46 isolates) and northern (4 isolates) Taiwan
were analyzed. These isolates included those from various
clinical specimens (blood and wound pus) of 50 patients
with V. vulnificus infection. All isolates of V. vulnificus
were identified by using conventional methods and the
O/129 susceptibility tests. Identification of the isolates was
further confirmed by the API 32 GN system (bioMérieux
Vitek, Inc., Hazelwood, MO). Pulsed-field gel elec-
trophoresis (PFGE) analysis was performed by a method
described previously by Tenover et al. (36,37). DNA was
digested by the restriction enzymes SfiI and NotI
(Promega, Madison, WI). All isolates were not identical in
PFGE profiles (50 pulsotypes were found), and only two
isolates from southern Taiwan were closely related (within
three bands of difference). These findings support the high
degree of heterogeneity among isolates of V. vulnificus that
cause human infections in Taiwan.
Preventive Measures
Residents of Taiwan, particularly those with preexisting
liver and other chronic, underlying medical conditions
(renal disease, diabetes mellitus, chronic steroid use),
should be educated in measures to prevent acquiring V. vul-
nificus infections. This bacterium is present in warm
coastal waters around Taiwan during the summer months,
particularly in the southern region. Exposing open wounds
or broken skin to warm salt or brackish water or to raw
marine animals harvested from such waters should be
avoided. Patients at high risk should wear protective cloth-
ing (e.g., gloves) when handling seafood (fish, oysters,
clams, shrimp, eels, and other shellfish) and not eat raw or
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Figure 3. Rates of deaths according to different types of infection
of 84 patients with Vibrio vulnificus infection.improperly cooked seafood. Because this disease is rapid-
ly progressive and deadly if not recognized promptly and
treated aggressively, any illness (such as fever or skin
lesions), which develops in patients at risk after contact
with marine animals or waters or ingestion of seafood
requires immediate medical care.
The government in Taiwan (Department of Health and
Council of Agriculture) should encourage food companies
to put warning labels on seafood containers, menus, and
public health brochures. The wording of such labeling
should be similar to the label required by the Florida
Department of Natural Resources for all wholesale shell
food and shucked products: “Consumer Information—
There is a risk associated with consuming raw oysters or
any raw animal protein. If you have chronic illness of the
liver, stomach, or blood or have immune disorders, you are
at a greater risk of serious illness from raw oysters and
should eat oysters fully cooked. If unsure of your risk, con-
sult a physician” (38).
Conclusion
Residents of Taiwan have a high prevalence of chronic
liver disease and are often exposed to marine microorgan-
isms present in the sea that surrounds the island or rivers,
lakes, or ponds inside the island. The presence of high
genetic divergence among V. vulnificus isolates from
humans and the environment indicates that this virulent
bacterium is ubiquitous in nature. When V. vulnificus is
suspected as the cause of sepsis, empiric therapy that
includes a third-generation cephalosporin and minocycline
should be administered. It should be standard practice for
physicians to advise patients with underlying medical ill-
ness to avoid eating raw or undercooked seafood and to
avoid exposing wounds to seawater. 
Dr. Hsueh is an associate professor in the departments of
Laboratory Medicine and Internal Medicine of National Taiwan
University Hospital and National Taiwan University College of
Medicine. His research interests include mechanisms of antimi-
crobial resistance and molecular epidemiology of emerging
pathogens. 
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